



## Press release

Stockholm, 14 January 2026

### Invitation: Sobi's Q4 and FY 2025 report

**Sobi plans to publish its report for the fourth quarter and full year of 2025 on 5 February 2026 at 08:00 CET.**

Investors, analysts, and the media are invited to a conference call on the same day at 13:00 CET, 12:00 GMT, and 07:00 EST. The call will include a presentation of the results and a Q&A session.

The presentation can be followed live [here](#) or afterwards on [sobi.com](#). The slides will be made available on [sobi.com](#) before the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031

United Kingdom: +44 207 107 06 13

United States: +1 631 570 56 13

For other countries, please find the details [here](#).

#### Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at [sobi.com](#) and [LinkedIn](#).

#### Contacts

For details on how to contact the Sobi Investor Relations Team, please click [here](#). For Sobi Media contacts, click [here](#).

Gerard Tobin

Head of Investor Relations